Background: Peripheral neuropathy (PN) is a common consequence of multiple myeloma (MM) among those commonly treated with older-generation proteasome inhibitors (PIs). In this study, we evaluated the economic burden attributable to PN among MM patients in realworld practice settings in the US. Methods: Adults diagnosed with MM and first treated (index event) between 1 July 2006 and 28 February 2017 were identified from MarketScan® Commercial and Medicare claim databases. Continuous enrollment for at least 12 months without treatment and PN diagnoses were required pre-index. Patients were followed for at least 3 months until inpatient death or end of data. The International Classification of Diseases, ninth revision, Clinical Modification (ICD-9-CM) and ICD-10-CM diagnosis codes were used to identify PN. Propensity-score matching was applied to match every patient with PN to two MM patients without a PN diagnosis (controls). Healthcare utilization and expenditures per patient per month (PPPM) in the postindex period were estimated. Results: Of 11,851 patients meeting the study criteria, 15.5% had PN. After matching 1387 patients with PN and 2594 controls were identified. Baseline characteristics were well balanced between cohorts; mean follow up was 23-26 months. PPPM total costs were significantly higher by $1509 for patients with PN than controls, driven by higher hospitalization (PN 77.4%, controls 67.2%; p < 0.001) and emergency department rates (PN 67.8%, controls 58.4%; p < 0.001) and more outpatient hospital-based visits PPPM (PN 13.5 ± 14.7, controls 11.5 ± 18.0; p < 0.001). Conclusions: PN is a prevalent MM treatment complication associated with a significant economic burden adding to the complexity and cost of MM treatment. Highly effective novel treatments such as carfilzomib may reduce the overall disease burden.
Introduction
Multiple myeloma (MM) is a systemic malignancy of plasma cells in bone marrow, with approximately 30,280 incident cases estimated to be diagnosed in the United States in 2017 (17,940 men and 12,790 women). MM primarily affects the elderly population since the median age at incidence is 69 years. 1, 2 For several decades, the standard treatment approach has been induction therapy followed by autologous stem-cell transplantation for transplant-eligible patients and high-dose chemotherapy for other patients. While the recent introduction of many novel therapies such as immunomodulating agents, proteasome inhibitors (PIs), monoclonal antibodies, and histone deacetylase inhibitor have shown improved response, progressionfree survival 3-9 and survival rates 10 in clinical trials, MM remains an incurable malignancy for the majority of patients. 11 Peripheral neuropathy (PN) is a common complication of MM and one of the main dose-limiting iatrogenic toxicities associated with some antimyeloma treatments, including older-generation PIs such as bortezomib. [12] [13] [14] [15] [16] The incidence of PN associated with MM treatments during the course of the disease and treatment has been estimated to range between 21% and 70% depending on the treatment and PN severity. 15 MM treatment options are often limited by the likelihood of therapies causing or exacerbating neuropathies with significant negative impacts on patient quality of life. 14,16 Treatment-induced PN, although usually reversible, can cause severe pain and affect the patient's activities of daily living, as well as causing serious problems, such as loss of sensation, balance issues, muscle weakness, and organ failure. [15] [16] [17] [18] Management of PN is an ongoing challenge for healthcare providers. Actions to mitigate the incidence and effects of PN may include dosage and dosing-schedule adjustments of PIs, PI treatment discontinuation, other modalities (e.g. electrical nerve stimulation, physical therapy, acupuncture, other), and medications to address the pain (e.g. topical analgesics, antidepressants, antiepileptics, opioids). 16, 19 These treatment measures for managing the effects of PN also carry an economic burden for the healthcare system (e.g. increased visits to monitor or treat the PN, costs of PN treatment), as well as significant financial and lifestyle repercussions for the MM patient.
The impact of PN on healthcare utilization and costs for MM patients treated in real-world practice settings is not well understood. The purpose of this study was to use real-world data to examine the healthcare resource utilization and costs associated with PN in patients being treated for MM, comparing those diagnosed with PN to a matched control cohort without PN.
Methods

Study design and data source
This retrospective, observational cohort study was based on administrative healthcare claims data from 1 January 2006 to 28 February 2017 from the IBM® MarketScan Commercial Claims and Encounters (Commercial) and Medicare Supplemental and Coordination of Benefits (Medicare) databases. These databases include inpatient medical, outpatient medical, and outpatient pharmacy claims data, as well as insurance enrollment and demographic information collected from a wide variety of health plans across the US. The Commercial database includes information for over 20 million individuals annually who are under the age of 65 years with employersponsored health insurance, including the primary insured, spouses and dependents. The Medicare Supplemental database includes both the Medicare-paid and supplemental-paid components of reimbursed insurance claims information for over 2 million individuals annually with both traditional and supplemental Medicare coverage. The study databases satisfy Sections 164.514 (a)-(b) (1) (ii) of the Health Insurance Portability and Accountability Act of 1996 privacy rule (HIPAA) regarding the determination and documentation of statistically de-identified data. This study used only de-identified patient records and did not involve the collection, use, or transmittal of individually identifiable data, and therefore institutional review board approval was not required.
Patient identification
Selected adult patients, 18 years of age and older, had at least one inpatient or two outpatient claims (from 30 to 365 days of the first found outpatient claim) with a diagnosis of MM based on International Classification of Diseases, ninth revision, Clinical Modification (ICD-9-CM) diagnosis codes 203.0x or ICD-10-CM (tenth revision) diagnosis codes C9000, C9001 and C9002 between 1 July 2006 and 28 February 2017, and at least one claim indicating the administration or prescription of an MM therapy (bendamustine, bortezomib, carfilzomib, cisplatin, cyclophosphamide, doxorubicin, doxorubicin liposomal, lenalidomide, melphalan, panobinostat, pomalidomide, thalidomide) on or after the date of the first MM diagnosis. Claims associated with a diagnostic workup such as laboratory tests or diagnostic X-rays were not used for patient selection. To ensure that patients were newly diagnosed and newly treated, a 12-month period with no diagnosis of MM prior to the first found (initial) MM diagnosis and a 12-month period with no MM therapy prior to the initial MM therapy was required. The index date was the date of the first claim for one of the MM therapies on or after the initial MM diagnosis.
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Continuous medical and prescription coverage was required for at least 12 months prior to the index date (preperiod), and for at least 3 months after the index date (postperiod). Patients were followed from the index date until the earliest evidence of inpatient death (via discharge status), end of continuous enrollment, or end of study period (28 February 2017). This process is described in Figure 1 .
Identification of peripheral neuropathy cases and matched controls
Due to the lack of diagnosis code specificity for disease-related or treatment-induced PN, PN was identified using an algorithm from previously published studies. 20,21 PN cases were identified by a medical claim with a diagnosis for PN (codes in Table A .1) during the 9 months following their initial MM therapy and without evidence of PN during the 12-month preperiod through the 7 days following the initial MM treatment ( Figure 2 ). Controls had no medical claims with a diagnosis of PN anytime during the 12-month preperiod and throughout the follow-up period.
To adjust for imbalances in demographics and clinical characteristics, patients with PN were matched to a pool of patients without PN in a ratio of 1:2 (PN:without PN) using propensityscore modeling with nearest-neighbor matching. Matching factors included patients' demographic characteristics [age, sex, geographic region of residence, payer (Commercial or Medicare), healthplan type] and baseline clinical characteristics (Deyo-Charlson Comorbidity Index, DCI) 22 and specific preindex comorbidities including cardiovascular disease, cerebrovascular disease, chronic obstructive pulmonary disease, rheumatoid arthritis, diabetes, chronic kidney disease, skeletal-related events, coagulopathies, hematologic disease, hypertension, and the index MM medication). Standardized differences in matching factors between patients with PN and patients without PN were calculated before and after the matching to examine the quality of the match.
Lines of therapy
This study used a previously published MM treatment algorithm to identify the number of lines of therapy. 21 The first line started on the date of the first MM chemotherapy or immunotherapy treatment with bendamustine, bortezomib, carfilzomib, cisplatin, cyclophosphamide, doxorubicin, doxorubicin liposomal, lenalidomide, melphalan, panobinostat, pomalidomide, or thalidomide. A treatment regimen was defined as consisting of one or more chemotherapy with or without immunotherapy agents administered within 90 days of the start of the line of therapy. A line of therapy ended at the earliest occurrence of a 90-day gap in all MM treatments in a regimen comprising the line of therapy, initiation of a different MM treatment > 90 days after the start of current line of therapy, inpatient discharge status of death, end of enrollment, or end of data. Note that lenalidomide monotherapy initiated within 60 days of the last drug administration in the line of therapy was classified as 'maintenance therapy'. Maintenance therapy was considered to be a continuation of the line of therapy and not a new line of therapy. Moreover, any MM therapy received within 90 days following a stem-cell transplant date was considered to be 'consolidation therapy' within the current line and not the start of a new line of therapy. All subsequent lines of therapy were identified using the same approach as for the first line (with the noted exception above regarding first-line maintenance). Patients with and without PN were identified during each line of therapy. Because of the small number of patients with more than three lines of therapy with PN, the third line and subsequent lines were combined in reporting.
Covariates and study outcomes Demographics data extracted on the index date, included age, sex, US Census Bureau geographic region, payer (Commercial insurance or Medicare), healthplan type, and index year. Baseline clinical characteristics, measured throughout the 12-month pre-index period, included the DCI (an aggregate measure of comorbidity expressed as a numeric score based on the presence of various diagnoses), specific conditions contained in the DCI, other primary cancers, and other diseaserelated complications. 22 Study outcomes included all-cause healthcare utilization and costs measured during the at-least-3-month follow-up period and stratified for occurrence during the first, second, or third (or higher) lines of therapy. Healthcare utilization and costs were categorized as inpatient medical, emergency department/room (ER), office visits, outpatient hospital-based visits, other outpatient services, and outpatient pharmacy. Due to the variable length of follow up for patients overall and during lines of therapy, healthcare utilization and costs were reported in per-patient-per-month units (PPPM). Costs used the total paid amounts from all payers to all providers, including planpaid, patient-paid, and coordinated benefit payments. All dollar amounts were inflation adjusted to 2017 US dollars using the Medical Care component of the Consumer Price Index. 23 The incidence rate of PN was calculated using the unmatched sample of all treated MM patients as the number of patients with PN divided by the person-time from the index date to the first PN diagnosis for PN patients, plus the person-time from the index date to the end of follow up for patients without PN. 
Statistical considerations
Pairwise descriptive statistics were used to compare demographics, comorbid conditions, healthcare utilization and costs between patient cohorts with and without PN after propensity-score matching. Descriptive statistics also evaluated these differences between the comparator cohorts during first line, second line, and third-plus-subsequent lines of therapy. Chi-squared tests were conducted for differences in dichotomous or categorical variables and t tests were conducted for comparisons of continuous variables. A p value < 0.05 was set as the threshold for statistically significant differences. Following propensity-score matching of PN patients and patients without PN, statistically significant postindex differences in results between cohorts were presumed to be associated with the effects of the key independent variable, the incidence of PN. Statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC, US).
Results
A total of 9207 patients comprising the case and control pool; 15.5% (1431 patients) were identified as having PN; 7776 had no PN diagnosis anytime during the study period ( Figure 1 Table 2) .
Use of narcotic pain medication was common and also higher among patients with PN compared with patients with no PN (during first-line therapy: 82% versus 72%; p < 0.001). 
Discussion
This study found significantly higher healthcare resource utilization and costs in patients with a post-treatment diagnosis for PN during their follow up compared with a matched group of patients without PN. Patients with PN were significantly more likely to be hospitalized, had an ER visit, had an outpatient hospital-based visit, and filled more outpatient prescriptions than matched patients without a PN diagnosis. This increased use of healthcare resource was associated with $1509 higher PPPM total costs, amounting to $36,216 over PN patients' mean 2-year follow-up time. Pike and colleagues, in a similar study using administrative US claims data (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) , estimated the costs for chemotherapy-induced PN in a matched cohort comparison of cancer patients (not MM) with and without post-treatment PN, finding that PN patients had higher mean total healthcare costs by $17,344 during the 12-month study period than comparable patients without PN. They further found that more PN cases were hospitalized, had an ER visit, and had other outpatient visits. 24 In a 2001 pilot study of chemotherapy-induced toxicity in ovarian cancer patients, Calhoun and colleagues found indirect costs, such as the cost of caregiver time and lost wages, to be a substantial contributor to the total burden of chemotherapy-induced toxicity. 25 The estimated marginal healthcare expenditure of $1509 PPPM attributable to PN in our study using direct medical and prescription expenditures derived from paid healthcare claims represents only a portion of the overall societal cost. Due to the lack of information, costs associated with caregiver burden, indirect costs, or the quality of life impact were not examined.
In our study, the rate of PN in MM patients was 15.5%, which appears low compared with other studies where PN rates ranged from over 20% to as high as 70% incidence. The population in this study is slightly younger overall due to larger representation from commercial carriers than from Medicare data providers. 1, 2 Obtaining optimal clinical efficacy requires carefully balancing treatment effectiveness with the potential for negative consequences on the patient's quality of life. The dosage reductions, treatment switches, or discontinuation of MM therapies to manage PN may ultimately affect response to therapy. 28 Thalidomide and bortezomib are associated with higher rates of PN. 12,13,15,16 Recent approval of novel therapies 29-32 hold promise for antimyeloma efficacy with reduced incidence of PN.
Limitations
There are several limitations associated with this study. Use of diagnosis coding from administrative claims data may be subject to misclassification errors, where the extent of undercoding for the selected conditions or comorbidities is unknown, and without the availability of patient charts or physician attestations. PN diagnoses may not be included on administrative claims unless the impairment significantly affects patient management, thereby under-reported or biased toward more severe cases. PN could not be identified directly in claims data because of the lack of diagnosis codes specific to disease-related and treatment-induced PN. Consequently, PN identification used an algorithm from a previously published study that has not been validated, and the PN could be due to other causes. This study used propensity-score matching to ensure cohorts had similar baseline demographic and clinical characteristics, increasing the likelihood that differences between cohorts were associated with PN. However, there is always the potential of unmeasured confounders outside of this study's data sources. In addition, the incremental healthcare utilization and costs in the PN cohort may not be directly linked to PN; it could also be due to PN treatment, PN complications, and other conditions that could not be controlled or adjusted for in the claims data. Pharmacological treatments that were based on pharmacy prescription claims only indicated that prescriptions were received, not necessarily how the patients took the medications. This is not an issue for medications administered in the physician's office and billed through a medical claim. Several 
